Eventide Healthcare & Life Sciences Fund Ranks Top 1% in Health Funds for the 5yr Period

BOSTON, MA – The Eventide Healthcare & Life Sciences Fund (NASDAQ: ETIHX*), which celebrated its five-year anniversary in December, completed the five-year period ending December 31, 2017 in the top 1% of the Morningstar Health category for total return out of 121 funds. The Fund ranked in the top 8% for the three-year period out of 129 funds, and top 2% for the one-year period out of 144 funds. The Wall Street Journal also named the Fund a “Category King” for 2017 for ranking in the top 10 Health & Biotech funds based on total return (ranking #3 out of 99 funds).

The Eventide Healthcare & Life Sciences Fund aims for outperformance by investing in healthcare and life sciences companies creating compelling value for patients and society. Lead portfolio manager Finny Kuruvilla, MD PhD commented, “Biotechnology is perhaps the most exciting and rewarding area to invest today. Scientific and technological advances have now made it possible to address previously intractable unmet medical needs. We focus on small, early development-stage companies developing novel treatments for some of the most devastating diseases afflicting humankind. We believe this approach offers investors the potential for outperformance and the satisfaction in helping to promote human health and wellness.”

Finny Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. He is assisted by research analyst Agustin Mohedas who holds a PhD in Medical Engineering Medical Physics from the Harvard-MIT Division of Health Sciences and Technology and a bachelor’s degree in Biomedical Engineering from Texas A&M University.


Morningstar, Inc. All rights reserved. Morningstar is an independent provider of financial information. Wall Street Journal and Morningstar rankings are not intended to constitute investment advice. Rather, you should use the rankings for informational purposes only. Rankings are only one form of performance measurement.

Morningstar percentile ranking is an investment’s total return percentile rank against others in its Morningstar Category,
ranging from 1 (best) to 100 (worst). The ranking does not account for sales loads, where applicable.

Wall Street Journal Category King is awarded to the top 10 investments in their Lipper Category based on one-year total
return absolute rank. The award does not account for sales loads, where applicable.

*Rankings differ for other fund classes, based upon fees and commissions. Other share classes: NASDAQ: ETNHX, NASDAQ:
ETAHX, NASDAQ: ETCHX.

There is no guarantee that the Adviser will meet its objectives. The backgrounds provided of research personnel does not imply a certain level of skill, and is for information purposes only.

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund’s ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency – fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.

An investor should consider a Fund’s investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.

4193-NLD-1/26/2018

News › Eventide Healthcare & Life Sciences Fund Ranks Top 1% in Health Funds for the 5yr Period

Mutual Funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Funds’ ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards.

The Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Funds can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. Investors in the Gilead Fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products.

Investors in the Eventide Multi-Asset Income Fund should be aware that interest rates are at historic lows and may change at any time based on government policy. In general, the price of a fixed income security falls when interest rates rise. A rise in interest rates may result in volatility and increased redemptions, which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices. Longer- term securities may be more sensitive to changes in interest rates. The intermediate-term bond portion of the Multi-Asset Income Fund’s portfolio may represent 0% to 100% of the Fund’s portfolio with an average duration of between two and eight years. The Eventide Multi-Asset Income Fund may invest in other funds. If other funds are utilized, such underlying funds are subject to investment advisory and other expenses, which will be indirectly paid by the Fund. As a result, your cost of investing in the Fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds. The Fund may invest, directly or indirectly, in “junk bonds.” Such securities are speculative investments that carry greater risks than higher quality debt securities. There are unique risks associated with REITs, preferred stocks, convertible bonds, and BDCs that are covered in the Fund's prospectus and SAI.

The Eventide Multi-Asset Income Fund and Eventide Global Dividend Opportunities Fund can invest in MLPs and Yieldcos. MLPs carry unique risks including risks surrounding its tax status and risk pertaining to rising interest rates, both of which can negatively impact share price. Yieldcos carry different risks including Yieldco Sponsor Risk and cash flow risk. The Eventide Global Dividend Opportunities Fund can invest in Industrials and Utilities. Companies in the Industrial Sector carry various risks including, but not limited to, risk related to debt loads, intense competition, and sensitivity to economic cycles. Companies in the Utilities sector are subject to interest rate risk and cash flow risk. The Eventide Global Dividend Opportunities Fund is a new mutual fund and has a limited history of operations for investors to evaluate.

An investor should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.